112 related articles for article (PubMed ID: 1810451)
1. Immunological properties of melanoma tumor-infiltrating lymphocytes before and after IL-2-based biotherapies.
Itoh K; Balch CM; Murray JL; Parkinson DR; Markowitz AB; Talpaz M; Lee K; Zukiwski AA; Ross MI; Legha SS
In Vivo; 1991; 5(6):647-53. PubMed ID: 1810451
[TBL] [Abstract][Full Text] [Related]
2. Alteration in interactions between tumor-infiltrating lymphocytes and tumor cells in human melanomas after chemotherapy or immunotherapy.
Itoh K; Hayakawa K; Salmeron MA; Legha SS; Murray JL; Talpaz M; Balch CM; Parkinson DR; Lee K; Zukiwski AA
Cancer Immunol Immunother; 1991; 33(4):238-46. PubMed ID: 2059968
[TBL] [Abstract][Full Text] [Related]
3. [Effects of auto-tumor infiltrating lymphocytes induced by interleukin (IL)-12 with IL-2 on patients of primary hepatic carcinoma].
Zhang YX; Wang XY; Liu JB; Zhang SQ; Chen YR
Zhonghua Yi Xue Za Zhi; 2008 Apr; 88(14):973-6. PubMed ID: 18756970
[TBL] [Abstract][Full Text] [Related]
4. Patterns of relapse and response to retreatment in patients with metastatic melanoma or renal cell carcinoma who responded to interleukin-2-based immunotherapy.
Lee DS; White DE; Hurst R; Rosenberg SA; Yang JC
Cancer J Sci Am; 1998; 4(2):86-93. PubMed ID: 9532410
[TBL] [Abstract][Full Text] [Related]
5. HLA association with response and toxicity in melanoma patients treated with interleukin 2-based immunotherapy.
Marincola FM; Venzon D; White D; Rubin JT; Lotze MT; Simonis TB; Balkissoon J; Rosenberg SA; Parkinson DR
Cancer Res; 1992 Dec; 52(23):6561-6. PubMed ID: 1423301
[TBL] [Abstract][Full Text] [Related]
6. Common expression of melanoma tumor-associated antigens recognized by human tumor infiltrating lymphocytes: analysis by human lymphocyte antigen restriction.
Hom SS; Topalian SL; Simonis T; Mancini M; Rosenberg SA
J Immunother (1991); 1991 Jun; 10(3):153-64. PubMed ID: 1868040
[TBL] [Abstract][Full Text] [Related]
7. Minimally cultured or selected autologous tumor-infiltrating lymphocytes after a lympho-depleting chemotherapy regimen in metastatic melanoma patients.
Besser MJ; Shapira-Frommer R; Treves AJ; Zippel D; Itzhaki O; Schallmach E; Kubi A; Shalmon B; Hardan I; Catane R; Segal E; Markel G; Apter S; Nun AB; Kuchuk I; Shimoni A; Nagler A; Schachter J
J Immunother; 2009 May; 32(4):415-23. PubMed ID: 19342963
[TBL] [Abstract][Full Text] [Related]
8. Clinical results and characterization of tumor-infiltrating lymphocytes with or without recombinant interleukin 2 in human metastatic renal cell carcinoma.
Bukowski RM; Sharfman W; Murthy S; Rayman P; Tubbs R; Alexander J; Budd GT; Sergi JS; Bauer L; Gibson V
Cancer Res; 1991 Aug; 51(16):4199-205. PubMed ID: 1868441
[TBL] [Abstract][Full Text] [Related]
9. Clinical observations on adoptive immunotherapy with vaccine-primed T-lymphocytes secondarily sensitized to tumor in vitro.
Chang AE; Yoshizawa H; Sakai K; Cameron MJ; Sondak VK; Shu S
Cancer Res; 1993 Mar; 53(5):1043-50. PubMed ID: 8439951
[TBL] [Abstract][Full Text] [Related]
10. Modifying interleukin-2 concentrations during culture improves function of T cells for adoptive immunotherapy.
Besser MJ; Schallmach E; Oved K; Treves AJ; Markel G; Reiter Y; Schachter J
Cytotherapy; 2009; 11(2):206-17. PubMed ID: 19148842
[TBL] [Abstract][Full Text] [Related]
11. Clinical and biological effects of intraperitoneal injections of recombinant interferon-gamma and recombinant interleukin 2 with or without tumor-infiltrating lymphocytes in patients with ovarian or peritoneal carcinoma.
Freedman RS; Kudelka AP; Kavanagh JJ; Verschraegen C; Edwards CL; Nash M; Levy L; Atkinson EN; Zhang HZ; Melichar B; Patenia R; Templin S; Scott W; Platsoucas CD
Clin Cancer Res; 2000 Jun; 6(6):2268-78. PubMed ID: 10873077
[TBL] [Abstract][Full Text] [Related]
12. In vitro enhanced cytotoxicity of tumor-infiltrating lymphocytes transfected with tumor necrosis factor-related apoptosis-inducing ligand and/or interleukin-2 gene in human renal cell carcinoma.
Tian JQ; Wang ZP; Rodriguez R; Fu JS; Lu JZ; Ma BL
Urology; 2006 May; 67(5):1093-8. PubMed ID: 16635513
[TBL] [Abstract][Full Text] [Related]
13. Current concepts of tumor-infiltrating lymphocytes in human malignancies.
Chiou SH; Sheu BC; Chang WC; Huang SC; Hong-Nerng H
J Reprod Immunol; 2005 Oct; 67(1-2):35-50. PubMed ID: 16111767
[TBL] [Abstract][Full Text] [Related]
14. Characterization of IL-2-activated TILs and their use in intrapericardial immunotherapy in malignant pericardial effusion.
Toh U; Fujii T; Seki N; Niiya F; Shirouzu K; Yamana H
Cancer Immunol Immunother; 2006 Oct; 55(10):1219-27. PubMed ID: 16362409
[TBL] [Abstract][Full Text] [Related]
15. Cytokine gene therapy of gliomas: induction of reactive CD4+ T cells by interleukin-4-transfected 9L gliosarcoma is essential for protective immunity.
Giezeman-Smits KM; Okada H; Brissette-Storkus CS; Villa LA; Attanucci J; Lotze MT; Pollack IF; Bozik ME; Chambers WH
Cancer Res; 2000 May; 60(9):2449-57. PubMed ID: 10811123
[TBL] [Abstract][Full Text] [Related]
16. Preoperative IL-2 immunotherapy enhances tumor infiltrating lymphocytes (TILs) in gastric cancer patients.
Romano F; Cesana G; Caprotti R; Bovo G; Uggeri F; Piacentini MG; Crippa S; Uggeri F
Hepatogastroenterology; 2006; 53(70):634-8. PubMed ID: 16995478
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic efficacy of melanoma-reactive TIL injected in stage III melanoma patients.
Labarrière N; Pandolfino MC; Gervois N; Khammari A; Tessier MH; Dréno B; Jotereau F
Cancer Immunol Immunother; 2002 Nov; 51(10):532-8. PubMed ID: 12384804
[TBL] [Abstract][Full Text] [Related]
18. Endogenous and adoptively transferred A-NK and T-LAK cells continuously accumulate within murine metastases up to 48 h after inoculation.
Hokland M; Kjaergaard J; Kuppen PJ; Nannmark U; Agger R; Hokland P; Basse P
In Vivo; 1999; 13(3):199-204. PubMed ID: 10459491
[TBL] [Abstract][Full Text] [Related]
19. Interleukin 2 activation of cytotoxic T-lymphocytes infiltrating into human metastatic melanomas.
Itoh K; Tilden AB; Balch CM
Cancer Res; 1986 Jun; 46(6):3011-7. PubMed ID: 3486040
[TBL] [Abstract][Full Text] [Related]
20. Randomized trial of adoptive transfer of melanoma tumor-infiltrating lymphocytes as adjuvant therapy for stage III melanoma.
Dréno B; Nguyen JM; Khammari A; Pandolfino MC; Tessier MH; Bercegeay S; Cassidanius A; Lemarre P; Billaudel S; Labarrière N; Jotereau F
Cancer Immunol Immunother; 2002 Nov; 51(10):539-46. PubMed ID: 12384805
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
